14,692 Shares in Boston Scientific Corporation $BSX Bought by AXQ Capital LP

AXQ Capital LP bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 14,692 shares of the medical equipment provider’s stock, valued at approximately $1,434,000. Boston Scientific accounts for 0.5% of AXQ Capital LP’s holdings, making the stock its 21st biggest holding.

A number of other institutional investors have also recently made changes to their positions in the stock. Compound Planning Inc. boosted its position in Boston Scientific by 22.1% during the third quarter. Compound Planning Inc. now owns 13,445 shares of the medical equipment provider’s stock valued at $1,313,000 after acquiring an additional 2,436 shares during the last quarter. Cary Street Partners Investment Advisory LLC lifted its stake in shares of Boston Scientific by 5.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after purchasing an additional 103 shares during the period. Fortis Capital Management LLC bought a new stake in shares of Boston Scientific during the 3rd quarter valued at about $5,895,000. Private Advisory Group LLC grew its stake in Boston Scientific by 9.3% during the third quarter. Private Advisory Group LLC now owns 2,392 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 204 shares during the period. Finally, Verus Capital Partners LLC increased its holdings in Boston Scientific by 38.6% in the third quarter. Verus Capital Partners LLC now owns 2,848 shares of the medical equipment provider’s stock worth $278,000 after purchasing an additional 793 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. JPMorgan Chase & Co. cut their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Barclays reduced their price target on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a report on Tuesday, February 3rd. UBS Group dropped their price objective on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, February 5th. Finally, Sanford C. Bernstein reissued an “outperform” rating and set a $112.00 price objective on shares of Boston Scientific in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average target price of $108.36.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $74.37 on Tuesday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The stock has a market cap of $110.36 billion, a PE ratio of 38.33, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67. The stock’s fifty day simple moving average is $88.87 and its two-hundred day simple moving average is $96.32. Boston Scientific Corporation has a 1-year low of $72.69 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the prior year, the business posted $0.70 EPS. The business’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.